1 **Molecular Epidemiology of SARS-CoV-2 in Cyprus**

2 Jan Richter^{a,e*}, Pavlos Fanis^{b,e}, Christina Tryfonos^{a,e}, Dana Koptides^{a,e}, George Krashias^{a,e},
3 Stavros Bashiardes^{a,e}, Andreas Hadjisavvas^{c,e}, Maria Loizidou^{c,e}, , Anastasis Oulas^{d,e}, Denise
4 Alexandrou^f, Olga Kalakouta^f, Mihalis I. Panayiotidis^{c,e}, George M. Spyrou^{d,e}, Christina
5 Christodoulou^{a,e}

6

7 **Affiliations:**

8 ^aMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia,
9 Cyprus

10 ^bMolecular Genetics, Function & Therapy Department, Cyprus Institute of Neurology and
11 Genetics, Nicosia, Cyprus

12 ^cCancer Genetics, Therapeutics & Ultrastructural Pathology Department, Cyprus Institute of
13 Neurology and Genetics, Nicosia, Cyprus

14 ^dBioinformatics Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

15 ^eThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics,
16 Nicosia, Cyprus

17 ^fMedical and Public Health Services, Ministry of Health, Nicosia, Cyprus

18

19 *Corresponding author

20 e-mail: richter@cing.ac.cy

21

22 **Keywords:** SARS-CoV-2, COVID-19, whole genome sequencing, epidemiology, Cyprus

23 Abstract

24 Whole genome sequencing of viral specimens following molecular diagnosis is a powerful
 25 analytical tool of molecular epidemiology that can critically assist in resolving chains of
 26 transmission, identifying of new variants or assessing pathogen evolution and allows a real-
 27 time view into the dynamics of a pandemic. In Cyprus, the first two cases of COVID-19 were
 28 identified on March 9, 2020 and since then 33,567 confirmed cases and 230 deaths were
 29 documented. In this study, viral whole genome sequencing was performed on 133 SARS-
 30 CoV-2 positive samples collected between March 2020 and January 2021. Phylogenetic
 31 analysis was conducted to evaluate the genomic diversity of circulating SARS-CoV-2
 32 lineages in Cyprus. 15 different lineages were identified that clustered into three groups
 33 associated with the spring, summer and autumn/winter wave of SARS-CoV2 incidence in
 34 Cyprus, respectively. The majority of the Cypriot samples belonged to the B.1.258 lineage
 35 first detected in September that spread rapidly and largely dominated the autumn/winter wave
 36 with a peak prevalence of 86% during the months of November and December. The B.1.1.7
 37 UK variant (VOC-202012/01) was identified for the first time at the end of December and
 38 spread rapidly reaching 37% prevalence within one month. Overall, we describe the changing
 39 pattern of circulating SARS-CoV-2 lineages in Cyprus since the beginning of the pandemic
 40 until the end of January 2021. These findings highlight the role of importation of new
 41 variants through travel towards the emergence of successive waves of incidence in Cyprus
 42 and demonstrate the importance of genomic surveillance in determining viral genetic
 43 diversity and the timely identification of new variants for guiding public health intervention
 44 measures.

45

46 Introduction

47 Corona Virus Disease-2019 (COVID-19) is a pulmonary disease caused by the Severe Acute
48 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus [1]. SARS-CoV-2 was first
49 detected in December 2019 in Wuhan city in the Hubei province of China in a patient with
50 acute pneumonia [2,3]. Following global spread of the virus, on March 11, 2020 the World
51 Health Organization (WHO) characterized COVID-19 as a pandemic, which is still ongoing
52 and as of February 24, 2021 over 110 million confirmed cases and 2.47 million deaths were
53 reported worldwide (<https://covid19.who.int/>).

54 The complete genome of SARS-CoV-2 isolated from a patient in Wuhan, China was initial
55 published on Jan 5, 2020 [2] and since then analysis of viral sequences worldwide is
56 continuous with more than 614,000 complete genomes currently available in public databases
57 such as the GISAID (<https://www.gisaid.org/>). The global real-time tracing of the viral
58 spread through whole genome sequencing is important in the race to timely identify the
59 emergence of novel SARS-CoV-2 variants that change the transmission, antigenic properties
60 and/or pathogenicity of the virus [4]. The recent identification of three major Variants of
61 Concern (VOC), with increased transmissibility and the potential to reduce vaccine
62 effectiveness has led to increased surveillance efforts worldwide [5,6].

63 The Republic of Cyprus is one of the countries in Europe least affected by the COVID-19
64 pandemic, presumably due to its rapid and effective response strategy that included high
65 number of COVID-19 tests, effective tracing and isolation of cases and their contacts together
66 with preventive measures (e.g. social distancing, wearing face masks and hand washing) [7].

67 In addition, being an island guaranteed high effectiveness of airport closure with regard to
68 importing of new cases. The first two cases of COVID-19 in Cyprus were identified on
69 March 9, 2020 and since then 33,567 confirmed cases and 230 deaths were documented
70 (<https://covid19.ucy.ac.cy/>).

71 The aim of our study was to analyse and evaluate the genomic diversity of circulating SARS-
72 CoV-2 lineages in Cyprus. We report 133 full genome sequences obtained from individuals
73 tested positive by RT-PCR between March 2020 and January 2021 and evaluate their
74 characteristics and relationship with the progression of the pandemic in Cyprus. Public
75 sharing and use of genomic analyses are important tools for disease surveillance systems to
76 track and trace acquired COVID-19 cases for more accurate decision making and appropriate
77 public health action.

78

79 **Materials and Methods**

80 **Sample collection**

81 The Department of Molecular Virology of Cyprus Institute of Neurology and Genetics was
82 assigned as the reference laboratory for SARS-CoV2 by the Cyprus Ministry of Health of the
83 Republic of Cyprus. More than 180,000 samples from public as well as private hospitals were
84 received and analysed since March 2020. For this retrospective observational study 133
85 SARS-CoV2 positive nasopharyngeal swabs obtained from patients referred for diagnostic
86 purposes between March 2020 and January 2021 were selected for full genome sequencing.
87 A random, unselected approach for sample selection was taken without pre-screening for
88 variants of interest to avoid sampling bias. The viral RNA had been previously detected using
89 a qRT-PCR assay and all samples selected had a cycle threshold value (Ct) lower than 30.
90 The study was approved by the Cyprus National Bioethics committee (EEBK 21.1.01.03).

91

92 **Next Generation Sequencing**

93 Total RNA was extracted from 200 µl of nasopharyngeal swab fluid in a final volume of 50
 94 µl, using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (Applied Biosystems) on a
 95 KingFisher™ Flex Purification System (Thermo Fisher Scientific). Libraries were prepared
 96 using the QIAseq SARS-CoV-2 Primer Panel in conjunction with the QIAseq FX DNA
 97 Library Kit (Qiagen) according to manufacturer's instructions. In brief, viral RNA was
 98 reverse transcribed to synthesize cDNA using random hexamers. cDNAs were amplified in
 99 two high-fidelity multiplex PCR reactions using two different primer pools that together
 100 cover the entire SARS-CoV2 genome. The two enriched pools per sample were combined,
 101 purified using AMPure XP beads (Beckman Coulter) and quantified using the Qubit dsDNA
 102 HS Assay kit (Invitrogen). Fragmentation, end-repair and A-tailing was performed in a
 103 combined reaction per sample using 200 ng DNA. Next, Illumina platform-specific adapters
 104 were ligated to both ends of the DNA fragments. Library size selection and purification were
 105 carried out using AMPure XP beads (Beckman Coulter) in two rounds (0.8x and 1x
 106 respectively). The libraries were quality analyzed using the Agilent High Sensitivity D1000
 107 ScreenTape on a 2200 TapeStation system (Agilent) and quantified using the Qubit dsDNA
 108 HS Assay kit (Invitrogen). Equimolar quantities of libraries were pooled (24 samples/pool)
 109 and sequenced on a Illumina MiSeq sequencer. All sequences obtained were deposited at the
 110 GISAID EpiCov database (www.gisaid.org).

111 **Mapping, alignment and lineage assignment**

112 The Burrows-Wheeler Aligner (BWA), version: 0.7.15 was used to map the raw reads to the
 113 coronavirus reference genome Wuhan-Hu-1 (NCBI ID:NC_045512.2) [8]. Duplicate reads,
 114 which are likely to be the results of PCR bias, were marked using Picard version: 2.6.0
 115 (<http://broadinstitute.github.io/picard/>). Samtools, version: 0.1.19, was used for additional

BAM/SAM file manipulations [9]. SNPs, amino acid replacements and indels were verified using the CoV-Glue web interface [10]. Aligned reads were validated using the Integrative Genomics Viewers v.2.9.2 and consensus sequences were extracted [11]. SARS-CoV2 lineages of the 133 sequences were assigned using the dynamic nomenclature tool PANGOLIN (<https://pangolin.cog-uk.io>) [12].

Phylogenetic analysis

All phylogenetic analyses were conducted in MEGA7 [13]. The alignment of consensus sequences was performed using MUSCLE. Bayesian information criterion (BIC) scores were calculated for different models to determine the best fitting nucleotide substitution model. In addition, jModelTest [14] was used for evaluating the best fitting nucleotide substitution model under BIC yielding the same result (TN93model + gamma distributed rates). This model was subsequently used to construct a Maximum Likelihood phylogenetic tree with 1000 bootstrap replicates. All positions containing alignment gaps and missing data were eliminated only in pairwise sequence comparisons.

Results and Discussion

Since the beginning of the pandemic and until the 24/2/2021, the Republic of Cyprus reported 33,567 SARS-CoV2 confirmed cases (3.63% of the population) along with 230 associated casualties (24.2/100,000) (<https://covid19.ucy.ac.cy/>). Based on the number of positives identified (see Fig 1) the course of the pandemic in Cyprus so far can be distinguished into three main phases: a first phase during Spring 2020, starting with the first two cases identified on the 9th of March that peaked in the first week of April that was contained with a nationwide lock-down and lasted approximately until June; a second phase during the summer that started after the re-opening of the airports; and a third phase (which is still

continuing) during autumn/winter that peaked at the beginning of January and accounted for the majority of all cases registered so far.

Overall, between the 11th of March 2020 and the 29th of January 2021, 15 different lineages were identified among the 133 samples sequenced (Table 1). As shown in Fig 3 the phylogenetic analysis is in support of the PANGOLIN lineages assignment and reveals a picture of independent distinct importations that are followed by local transmission (Fig 3). In the bubble chart in Fig 2 three groups of lineages are clearly distinguishable and associate with the three phases of the SARS-CoV2 pandemic.

During the spring wave four variants (B.1.1.74, B.1.1.277, B.1.235 and B.1.1.251) were identified reflecting several independent importation events followed by local transmission. However, concomitant with the decline in reported positive cases following the country-wide lockdown, by the end of June these SARS-CoV-2 variants were no longer detected and none of these re-emerged during the second or the third wave.

Following the re-opening of the airports, the summer months of July and August were characterized by multiple distinct introductions of a variety of new lineages (B.1.36, B.1.236, B.1.2, B.1.1.67, B.1.1.288, B.1.1.192), which marked the beginning of a small second wave (Fig 3). The majority of the samples belonged to lineage B.1.2 and B.1.236 accounting for 86% of the samples in that wave, however, all these lineages again subsequently vanished. The B.1.2 lineage has been otherwise observed only infrequently in Europe, but has been very common in the United States and in Canada [15].

In September, two new lineages were identified for the first time, which were set to dominate the autumn/winter wave until December, namely the B.1.177 and the B.1.258 variants.

The B.1.177 lineage, which is characterized by the A222V spike mutation, was previously been shown to have emerged in Spain in early summer and subsequently became widespread

across Europe as well as Canada, accounting for the majority of sequences by autumn 2020 [16,17]. However, no evidence of increased transmissibility of this variant was reported [18]. In Cyprus, this lineage was first identified on the 19th of September and continued to circulate until the end of January at a relatively low but constant frequency fluctuating between 4% and 15 %.

In September, the B.1.258 lineage was introduced, which spread rapidly and largely dominated the autumn/winter wave with a peak prevalence of 86% during the months of November and December.

All samples belonging to the B.1.258 variant identified in Cyprus contain the six-nucleotide Δ H69/V70 deletion in the S gene, which was recently proposed to be labelled B.1.258 Δ [19].

This deletion, which has been shown to enhance viral infectivity [20] has arisen at least six times independently and frequently followed receptor binding AA replacements (i.e. N501Y, N439K, Y453F) ([19]). In addition, the B.1.258 variant is characterised by the N439K mutation that confers an increased binding affinity to the hACE2 receptor and leads simultaneously to immune escape from a panel of neutralizing monoclonal antibodies as well as from sera of persons recovered from infection [21].

By the end of December, the B.1.1.7 UK variant, also known as 20I/501Y.V1 and Variant of Concern 202012/01 (VOC-202012/01), was identified for the first time in the Cypriot sample set. This lineage was first reported on the 20th December in the United Kingdom and drew immediate attention due to its rapid spread and increased transmissibility [22]. The earliest sampled genome of the B.1.1.7 variant dates back to the 20th of September. Since then it has grown rapidly in frequency in the UK becoming the most prevalent lineage there with a similar development also observed in a variety of other European countries, including Ireland, Spain and Greece [23]. It is characterised by an unusual large number of genetic

changes including the receptor-binding domain and it is speculated that it may have originated in a chronically infected immunocompromised person. In our sample set the frequency of this variant increased in a similar rapid manner from 3.4% in December to 38 % by the end of January despite declining case numbers highlighting its superior fitness.

Conclusions

Whole genome sequencing of viral specimens following molecular diagnosis is a powerful analytical tool of molecular epidemiology that can critically assist in resolving chains of transmission, identifying of new variants or assessing pathogen evolution and allows a real-time view into the dynamics of a pandemic [24]. In this study we describe for the first time the changing pattern of circulating SARS-CoV-2 lineages in Cyprus since its appearance between March 2020 and the end of January 2021. Distinct lineages of SARS-CoV-2 contributing to three separate waves of infections reflective of the epidemiological pattern were observed.

The global real-time tracing of the viral spread through whole genome sequencing has led recently to the identification of three major Variants of Concern (VOC). Lineage B.1.1.7 (20I/501Y.V1, VOC-202012/01) better known as the UK variant possesses an unusual high number of mutations is believed to be more transmissible than the wild-type virus. Lineage B.1.351 (501.V2, 20H/501Y.V2, VOC-202012/02) first detected and reported in South Africa in early October 2020, shares several mutations with B.1.1.7 and is feared to reduce to some extent vaccine effectiveness [25]. In Brazil, the P.1 (20J/501Y.V3, VOC-202101/02) lineage emerged in December 2020 [26]. The P.1 lineage contains ten mutations in the spike protein that may affect its ability to be recognized by antibodies [27,28].

Of these three VOC only the B.1.1.7 variant has so far been identified in Cyprus, which after being encountered for the first time at the end of December was able to reach 37% prevalence within one month. The majority of the Cypriot samples analysed belonged to the B.1.258Δ lineage, which has been first detected at the beginning of August in Switzerland and has since then spread to numerous European countries where it became one of the most prevalent lineages by December including the Czech Republic, Slovakia and Sweden [19,29]. The N439K receptor binding motif characteristic of this lineage has previously been reported to confer an increased binding affinity to the hACE2 receptor and simultaneously leading to immune escape from a panel of neutralizing monoclonal antibodies as well as from sera of persons recovered from infection [21]. The association of mutations found in the B.1.258Δ lineage with increased fitness and immune evasion along with the high prevalence in several European countries stipulates further characterisation of this variant. A continuous surveillance of SARS-CoV2 by whole genome sequencing continues to be critical for timely detection of emerging variants, identifying transmission modes and guiding public health intervention.

Declaration of conflicting interest

All authors declare that there is no conflict of interest.

Funding

The study was supported by seed funding from The Cyprus Institute of Neurology and Genetics.

	Lineage	First detected	Last detected	Mar-20	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Total
Spring Wave	B.1.1.74	11/03/20	10/06/20	1	2	1	1								5
	B.1.1.277	22/03/20	25/03/20	3											3
	B.1.235	17/04/20	17/04/20		1										1
	B.1.1.251	27/04/20	05/05/20		1	1									2
Summer wave	B.1.36	11/07/20	11/07/20					1							1
	B.1.236	17/07/20	18/08/20					5	2						7
	B.1.2	05/08/20	23/09/20						10	7					17
	B.1.1.67	13/08/20	13/08/20					1							1
	B.1.1.288	19/08/20	19/08/20					1							1
	B.1.1.192	27/08/20	27/08/20					1							1
Autumn/Winter wave	B.1.177	16/09/20	26/01/21							1	3	2	1	2	9
	B.1.258	23/09/20	27/01/21							7	16	12	25	13	73
	B.1.1.103	28/12/20	29/12/20										2		2
	B.1.1.7	28/12/20	27/01/21										1	9	10
				4	4	2	1	6	15	15	19	14	29	24	133

234

235 **Table 1.** Time course of SARS-CoV2 lineages identified in Cyprus between March 2020 and
236 January 2021.

237

238

239

240 **Fig 1.** Daily number of positive SARS-CoV2 cases in Cyprus identified between March 2020
 241 and January 2021 (<https://covid19.ucy.ac.cy/>). The start of the implementation as well as the
 242 lifting of important governmental pandemic control measures are indicated.

Fig 2. Bubble chart illustrating the pattern of SARS-CoV2 lineages identified per month. The size of the circle is proportional to the number of samples.

249 **Fig 3.** Phylogenetic analysis of full genome sequences of 133 Cypriot strains aligned against
250 the reference genome hCoV-19/Wuhan/Hu-1/2019 (NC_045512.2). Sample names consist of
251 internal laboratory code followed by the date of sampling. The percentages of replicate trees
252 in which the associated taxa clustered together in the standard bootstrap test (1000 replicates)
253 are shown next to the branches. Only bootstrap values >70% are shown.

254

255

References

1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*. Nature Research; 2020. pp. 536–544. doi:10.1038/s41564-020-0695-z
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020;579: 265–269. doi:10.1038/s41586-020-2008-3
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382: 727–733. doi:10.1056/nejmoa2001017
4. consortiumku.muitrosnocgoc@tcatnoc TC-19 GU (COG-U. An integrated national scale SARS-CoV-2 genomic surveillance network. *The Lancet Microbe*. 2020;1: e99–e100. doi:10.1016/s2666-5247(20)30054-9
5. Mitze T, Rode J. Early assessment of epidemiological trends associated with SARS-CoV-2 variants of concern in Germany. *medRxiv*. 2021; 2021.02.16.21251803. doi:10.1101/2021.02.16.21251803
6. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ*. 2021;372: n579. doi:10.1136/bmj.n579
7. Quattrocchi A, Mamais I, Tsioutis C, Christaki E, Constantinou C, Koliou M, et al. Extensive Testing and Public Health Interventions for the Control of COVID-19 in the Republic of Cyprus between March and May 2020. *J Clin Med*. 2020;9: 3598.

279 doi:10.3390/jcm9113598

280 8. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
281 transform. *Bioinformatics*. 2009;25: 1754–1760. doi:10.1093/bioinformatics/btp324

282 9. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
283 Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25: 2078–2079.
284 doi:10.1093/bioinformatics/btp352

285 10. Singer JB, Gifford RJ, Cotten M, Robertson DL. CoV-GLUE: A Web Application for
286 Tracking SARS-CoV-2 Genomic Variation. 2020 [cited 1 Mar 2021].
287 doi:10.20944/preprints202006.0225.v1

288 11. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al.
289 Integrative genomics viewer. *Nature Biotechnology*. *Nat Biotechnol*; 2011. pp. 24–26.
290 doi:10.1038/nbt.1754

291 12. Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic
292 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat*
293 *Microbiol*. 2020;5: 1403–1407. doi:10.1038/s41564-020-0770-5

294 13. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis
295 Version 7.0 for Bigger Datasets. *Mol Biol Evol*. 2016;33: 1870–1874.
296 doi:10.1093/molbev/msw054

297 14. Darriba D, Taboada GL, Doallo R, Posada D. JModelTest 2: More models, new
298 heuristics and parallel computing. *Nat Methods*. 2012;9: 772. doi:10.1038/nmeth.2109

299 15. Pater AA, Bosmeny MS, Barkau CL, Ovington KN, Chilamkurthy R, Parasrampur
300 M, et al. Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the
301 United States. *bioRxiv*. 2021; 2021.01.11.426287. doi:10.1101/2021.01.11.426287

- 302 16. Guthrie JL, Teatero S, Zittermann S, Chen Y, Sullivan A, Rilkoff H, et al. Detection of
303 the novel SARS-CoV-2 European lineage B.1.177 in Ontario, Canada. medRxiv.
304 medRxiv; 2020. p. 2020.11.30.20241265. doi:10.1101/2020.11.30.20241265
- 305 17. Pwg M, Leon GA, Barra de E, Patrick Mallon P. Whole-genome sequencing of
306 SARS-CoV-2 in the Republic of Ireland during waves 1 and 2 of the pandemic.
307 medRxiv. 2021; 2021.02.09.21251402. doi:10.1101/2021.02.09.21251402
- 308 18. Hodcroft EB, Zuber M, Nadeau S, Crawford KHD, Bloom JD, Veessler D, et al.
309 Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of
310 2020. medRxiv. medRxiv; 2020. p. 2020.10.25.20219063.
311 doi:10.1101/2020.10.25.20219063
- 312 19. Brejová B, Hodorová V, Boršová K, Čabanová V, Reizigová L, Paul ED, et al.
313 B.1.258 Δ H69/V70, a SARS-CoV-2 variant with Δ H69/ Δ V70 in the Spike
314 protein circulating in the Czech Republic and Slovakia. 2021 [cited 2 Mar 2021].
315 Available: <http://arxiv.org/abs/2102.04689>
- 316 20. Kemp SA, Datir RP, Collier DA, Ferreira IATM, Carabelli A, Harvey W, et al.
317 Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion Δ H69/V70.
318 bioRxiv. bioRxiv; 2020. p. 2020.12.14.422555. doi:10.1101/2020.12.14.422555
- 319 21. Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj
320 JA, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while
321 evading antibody-mediated immunity. Cell. 2021;184. doi:10.1016/j.cell.2021.01.037
- 322 22. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK
323 defined by a novel set of spike mutations - SARS-CoV-2 coronavirus / nCoV-2019
324 Genomic Epidemiology - Virological. [cited 2 Mar 2021]. Available:
325 <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars->

- 326 cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563
- 327 23. RAPID RISK ASSESSMENT: SARS-CoV-2 increased circulation of variants of
 328 concern and vaccine rollout in the EU/EEA, 14th update. [cited 2 Mar 2021].
 329 Available: [https://www.ecdc.europa.eu/sites/default/files/documents/RRA-covid-19-](https://www.ecdc.europa.eu/sites/default/files/documents/RRA-covid-19-14th-update-15-feb-2021.pdf)
 330 14th-update-15-feb-2021.pdf
- 331 24. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. NextStrain:
 332 Real-time tracking of pathogen evolution. *Bioinformatics*. 2018;34: 4121–4123.
 333 doi:10.1093/bioinformatics/bty407
- 334 25. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al.
 335 Emergence and rapid spread of a new severe acute respiratory syndrome-related
 336 coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.
 337 medRxiv. medRxiv; 2020. p. 2020.12.21.20248640.
 338 doi:10.1101/2020.12.21.20248640
- 339 26. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus:
 340 preliminary findings - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology
 341 - Virological. [cited 4 Mar 2021]. Available: [https://virological.org/t/genomic-](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586)
 342 characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-
 343 findings/586
- 344 27. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Krammer F, Simon V, et al. The
 345 E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish
 346 neutralizing activity of human convalescent and post-vaccination sera. medRxiv Prepr
 347 Serv Heal Sci. 2021 [cited 4 Mar 2021]. doi:10.1101/2021.01.26.21250543
- 348 28. Liu Z, VanBlargan LA, Rothlauf PW, Bloyet LM, Chen RE, Stumpf S, et al.
 349 Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that

350 attenuate monoclonal and serum antibody neutralization. bioRxiv. bioRxiv; 2020.
 351 doi:10.1101/2020.11.06.372037

352 29. Brandt¹ C, Spott¹ R, Hölzer² M, Kühnert³ D, Fuchs² S, Lohde¹ M, et al. Molecular
 353 epidemiology of SARS-CoV-2 - a regional to global perspective. medRxiv. 2021;
 354 2021.01.25.21250447. doi:10.1101/2021.01.25.21250447

355